News & Resources
Innovation Trends in AD Research –the shift to increasingly individualised trial design, therapeutics and care.
Innovation Trends in AD Research –the shift to increasingly individualised trial design, therapeutics and care. Alzheimer’s disease (AD) research is entering a new phase of innovation, highlighted by a number of advances presented at recent conferences such as CTAD 2024 in Madrid and AD/PD 2025 in Vienna.
Interim results for six months ending 31 March 2025
20 May 2025 IXICO plc (AIM: IXI), a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announces its unaudited interim results for the six months ended 31 March 2025 (‘H1 2025’ or the ‘period’). Financial highlights Revenues up 26% to £3.
Imaging - Advancing Biomarker Research for Alzheimer’s Disease Diagnosis
Imaging: Advancing Biomarker Research for Alzheimer's Disease Diagnosis In an article published in the latest edition of the Journal for Clinical Studies, IXICO’s Chief Scientific Officer Robin Wolz outlines how data from the landmark Bio-Hermes study, sponsored by the Global Alzheimer's Platform Foundation (GAP) and supported by IXICO as imaging partner, can help better understand the…
Half-year Trading update - FY2025
16 April 2025: IXICO plc (AIM: IXI), the medical imaging advanced analytics company delivering intelligent insights in neuroscience, today provides a trading update ahead of its interim results for the six months ended 31 March 2025.
Discussing research multi-biomarker advances in Alzheimer’s Disease at ADPD 2025
This week we will be at the ADPD 2025 International Conference talking about some of our latest biomarker research. Specifically, we are presenting an AI-based approach to differentiate different types of dementia from magnetic resonance imaging (MRI).
Huntington's Disease: Your Imaging Analysis & Operations Solutions Partner
Transforming clinical research in Huntington’s diseaseEstablished for over 20 years, IXICO is the leading provider of neuroimaging services for Huntington’s disease (HD) clinical trials. Our mission is to advance investigational therapies through innovative imaging solutions that comply with global regulatory standards.
Your Imaging Analysis & Operations Experts in Alzheimer’s Disease Clinical Research
IXICO’s Alzheimer’s Disease Footprint at a GlancePioneering Precision in AD Imaging IXICO excels in AD imaging with advanced imaging biomarkers to quantify markers such as amyloid plaques, tau tangles, and brain atrophy. Our AI-driven IXIQ. Ai platform enhances the accuracy and efficiency of brain imagine measurements.
1-8 of 159 results